Please add the following new claims:

--69. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

R^2 GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC
TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC
AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG
GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT
GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG
TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG
TTG TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N-terminally shortened sequence thereof, wherein R^2 is absent or is a DNA comprising a sequence coding for a polypeptide which can be cleaved *in vivo*; and

B) DNA comprising the sequence:

R^2 GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC
TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC
AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG
GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT
GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG
TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG
TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC
TCA GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or represents DNA coding for a polypeptide which can be cleaved *in vivo*.

70. Polypeptide according to claim 69, wherein R^2 is a DNA comprising a sequence which codes for a polypeptide which can be cleaved *in vivo*.

71. Polypeptide according to claim 69, wherein R^2 is a DNA comprising the sequence: CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof.

72. Polypeptide according to claim 69, wherein R^2 is a DNA encoding an amino acid sequence comprising: leu val pro his leu gly asp arg glu lys arg, or a C- and/or N- terminally shortened sequence thereof.

73. Polypeptide according to claim 70, wherein R^2 is a DNA comprising the sequence: R^3 CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA, or a C- and/or N- terminally shortened sequence thereof, wherein R^3 is a DNA coding for a signal peptide.

74. Polypeptide according to claim 70, wherein R^2 is a DNA encoding an amino acid sequence comprising: R^3 leu val pro his leu gly asp arg glu lys arg, or a C- and/or N-terminally shortened sequence thereof, wherein R^3 is a DNA coding for a signal peptide.

75. Polypeptide according to claim 73, wherein R^3 is a DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA

; or a C- and/or N- terminally shortened sequence thereof.

76. Polypeptide according to claim 73, wherein R^3 is a DNA encoding an amino acid sequence comprising:

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly													

; or a C- and/or N- terminally shortened sequence thereof.

77. Polypeptide according to claim 69, wherein said polypeptide is not associated with human urinary proteins.

78. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

```
                                                                GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT
```

, or a C- and/or N- terminally shortened sequence thereof; and

D) DNA comprising the sequence:

```
                                                                GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA
```

, or a C- and/or N- terminally shortened sequence thereof.

79. Polypeptide according to claim 78, wherein said polypeptide is not associated with human urinary proteins.

80. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is encoded by DNA selected from the group consisting of:

A) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

B) DNA comprising the sequence:

ATG CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

, or a C- and/or N- terminally shortened sequence thereof;

C) DNA comprising the sequence:

ATG GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

D) DNA comprising the sequence:

ATG GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

, or a C- and/or N- terminally shortened sequence thereof;

E) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG

E' cont.

ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

F) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT
GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA

, or a C- and/or N- terminally shortened sequence thereof;

G) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT
GGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA

E' cont.

E

AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG
TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG
GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC
AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT
CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG
TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA
AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG
ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC
ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG
TGC CTA CCC CAG ATT GAG AAT

, or a C- and/or N- terminally shortened sequence thereof;

H) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT
GGA GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA
AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC
TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC
AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC
CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG
GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC
GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT
GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT
GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG
TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT
GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG
TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC
TCA GGC ACC ACA

, or a C- and/or N- terminally shortened sequence thereof; and

I) DNA comprising the sequence:

ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCA CTG GTG
CTC CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT
GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT
GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG
ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT

GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT
GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC
TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG
GAG ATC TCT TCT TGC ACA GTG GAC CGG GAC ACC GTG TGT GGC
TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG
CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC
CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT
AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA
CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC
ACA GTG CTG TTG CCC CTG GTC ATT TTC TTT GGT CTT TGC CTT
TTA TCC CTC CTC TTC ATT GGT TTA ATG TAT CGC TAC CAA CGG
TGG AAG TCC AAG CTC TAC TCC ATT GTT TGT GGG AAA TCG ACA
CCT GAA AAA GAG GGG GAG CTT GAA GGA ACT ACT ACT AAG CCC
CTG GCC CCA AAC CCA AGC TTC AGT CCC ACT CCA GGC TTC ACC
CCC ACC CTG GGC TTC AGT CCC GTG CCC AGT TCC ACC TTC ACC
TCC AGC TCC ACC TAT ACC CCC GGT GAC TGT CCC AAC TTT GCG
GCT CCC CGC AGA GAG GTG GCA CCA CCC TAT CAG GGG GCT GAC
CCC ATC CTT GCG ACA GCC CTC GCC TCC GAC CCC ATC CCC AAC
CCC CTT CAG AAG TGG GAG GAC AGC GCC CAC AAG CCA CAG AGC
CTA GAC ACT GAT GAC CCC GCG ACG CTG TAC GCC GTG GTG GAG
AAC GTG CCC CCG TTG CGC TGG AAG GAA TTC GTG CGG CGC CTA
GGG CTG AGC GAC CAC GAG ATC GAT CGG CTG GAG CTG CAG AAC
GGG CGC TGC CTG CGC GAG GCG CAA TAC AGC ATG CTG GCG ACC
TGG AGG CGG CGC ACG CCG CGG CGC GAG GCC ACG CTG GAG CTG
CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC TGC CTG
GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC GCC GCC CTC CCG
CCC GCG CCC AGT CTT CTC AGA

, or a C- and/or N- terminally shortened sequence thereof.

81. Polypeptide according to claim 80, wherein said polypeptide is not associated with human urinary proteins.

82. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 69 under conditions of moderate stringency.

83. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

R^2	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp		
	ser	glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu
	asn	gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr
	val	cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu
	cys	val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr
	lys	leu	cys	leu	pro	gln	ile	glu	asn					

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or is a polypeptide which can be cleaved *in vivo*; and

B) a polypeptide comprising the amino acid sequence:

R^2	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln	asn
	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr	leu
	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys	arg
	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his	leu
	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met	gly
	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr	val
	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser	glu
	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn	gly
	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val	cys
	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys	val
	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys	leu
	cys	leu	pro	gln	ile	glu	asn	val	lys	gly	thr	glu	asp	ser
	gly	thr	thr											

, or a C- and/or N- terminally shortened sequence thereof, wherein R^2 is absent or is a polypeptide which can be cleaved *in vivo*.

84. Polypeptide according to claim 83, wherein R^2 is a polypeptide comprising an amino acid sequence which can be cleaved *in vivo*.

85. Polypeptide according to claim 84, wherein R^2 is a polypeptide comprising the amino acid sequence :

met	gly	leu	ser	thr	val	pro	asp	leu	leu	leu	pro	leu	val
leu	leu	glu	leu	leu	val	gly	ile	tyr	pro	ser	gly	val	ile
gly													

; or a C- and/or N- terminally shortened sequence thereof.

86. Polypeptide according to claim 83, wherein said polypeptide is not associated with human urinary proteins.

87. A polypeptide having the ability to bind to TNF comprising an amino acid sequence as set forth in claim 83 with at least one intrasequence conservative amino acid substitution in the sequence of claim 83.

88. Polypeptide according to claim 87, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

89. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

90. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

91. Polypeptide according to claim 90, wherein said polypeptide includes a methionine at the amino-terminus.

92. Polypeptide according to claim 88, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

93. Polypeptide according to claim 87, wherein said polypeptide includes a methionine at the amino-terminus and said amino acid substitution is at a glycosylation site.

94. Polypeptide according to claim 87, wherein said amino acid substitution is at a glycosylation site.

95. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, characterized in that the polypeptide is encoded by a nucleic acid which hybridizes with DNA complementary to the DNA defined in claim 83 under conditions of moderate stringency.

96. Polypeptide according to claim 83, wherein said polypeptide is selected from the group consisting of:

A) a polypeptide comprising the amino acid sequence:

asp ser val cys pro gln gly lys tyr ile his pro gln asn
asn ser ile cys cys thr lys cys his lys gly thr tyr leu
tyr asn asp cys pro gly pro gly gln asp thr asp cys arg
glu cys glu ser gly ser phe thr ala ser glu asn his leu
arg his cys leu ser cys ser lys cys arg lys glu met gly
gln val glu ile ser ser cys thr val asp arg asp thr val
cys gly cys arg lys asn gln tyr arg his tyr trp
ser glu asn leu phe gln cys phe asn cys ser leu cys leu
asn gly thr val his leu ser cys gln glu lys gln asn thr
val cys thr cys his ala gly phe phe leu arg glu asn glu
cys val ser cys ser asn cys lys lys ser leu glu cys thr
lys leu cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

leu val pro his leu gly asp arg glu lys arg asp ser val
cys pro gln gly lys tyr ile his pro gln asn asn ser ile
cys cys thr lys cys his lys gly thr tyr leu tyr asn asp
cys pro gly pro gly gln asp thr asp cys arg glu cys glu
ser gly ser phe thr ala ser glu asn his leu arg his cys
leu ser cys ser lys cys arg lys glu met gly gln val glu
ile ser ser cys thr val asp arg asp thr val cys gly cys
arg lys asn gln tyr arg his tyr trp ser glu asn leu phe
gln cys phe asn cys ser leu cys leu asn gly thr val his
leu ser cys gln glu lys gln asn thr val cys thr cys his

ala gly phe phe leu arg glu asn glu cys val ser cys ser
asn cys lys lys ser leu glu cys thr lys leu cys leu pro
gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

asp ser val cys pro gln gly lys tyr ile his pro gln asn
asn ser ile cys cys thr lys cys his lys gly thr tyr leu
tyr asn asp cys pro gly pro gly gln asp thr asp cys arg
glu cys glu ser gly ser phe thr ala ser glu asn his leu
arg his cys leu ser cys ser lys cys arg lys glu met gly
gln val glu ile ser ser cys thr val asp arg asp thr val
cys gly cys arg lys asn gln tyr arg his tyr trp ser glu
asn leu phe gln cys phe asn cys ser leu cys leu asn gly
thr val his leu ser cys gln glu lys gln asn thr val cys
thr cys his ala gly phe phe leu arg glu asn glu cys val
ser cys ser asn cys lys lys ser leu glu cys thr lys leu
cys leu pro gln ile glu asn val lys gly thr glu asp ser
gly thr thr

, or a C- and/or N- terminally shortened sequence thereof; and

D) a polypeptide comprising the amino acid sequence:

leu val pro his leu gly asp arg glu lys arg asp ser val
cys pro gln gly lys tyr ile his pro gln asn asn ser ile
cys cys thr lys cys his lys gly thr tyr leu tyr asn asp
cys pro gly pro gly gln asp thr asp cys arg glu cys glu
ser gly ser phe thr ala ser glu asn his leu arg his cys
leu ser cys ser lys cys arg lys glu met gly gln val glu
ile ser ser cys thr val asp arg asp thr val cys gly cys
arg lys asn gln tyr arg his tyr trp ser glu asn leu phe
gln cys phe asn cys ser leu cys leu asn gly thr val his
leu ser cys gln glu lys gln asn thr val cys thr cys his
ala gly phe phe leu arg glu asn glu cys val ser cys ser
asn cys lys lys ser leu glu cys thr lys leu cys leu pro
gln ile glu asn val lys gly thr glu asp ser gly thr thr

, or a C- and/or N- terminally shortened sequence thereof.

97. Polypeptide according to claim 96, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

98. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus and at the carboxyl-terminus.

99. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the amino-terminus.

100. Polypeptide according to claim 99, wherein said polypeptide includes a methionine at the amino-terminus.

101. Polypeptide according to claim 97, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

102. Polypeptide according to claim 96, wherein said polypeptide is not associated with human urinary proteins.

103. A recombinant polypeptide which is nonglycosylated or has a glycosylation pattern different from urinary-derived TNF inhibitor and has the ability to bind to TNF, wherein said polypeptide is selected from the group consisting of: :

A) a polypeptide comprising the amino acid sequence:

met	asp	ser	val	cys	pro	gln	gly	lys	tyr	ile	his	pro	gln
asn	asn	ser	ile	cys	cys	thr	lys	cys	his	lys	gly	thr	tyr
leu	tyr	asn	asp	cys	pro	gly	pro	gly	gln	asp	thr	asp	cys
arg	glu	cys	glu	ser	gly	ser	phe	thr	ala	ser	glu	asn	his
leu	arg	his	cys	leu	ser	cys	ser	lys	cys	arg	lys	glu	met
gly	gln	val	glu	ile	ser	ser	cys	thr	val	asp	arg	asp	thr
val	cys	gly	cys	arg	lys	asn	gln	tyr	arg	his	tyr	trp	ser
glu	asn	leu	phe	gln	cys	phe	asn	cys	ser	leu	cys	leu	asn
gly	thr	val	his	leu	ser	cys	gln	glu	lys	gln	asn	thr	val
cys	thr	cys	his	ala	gly	phe	phe	leu	arg	glu	asn	glu	cys
val	ser	cys	ser	asn	cys	lys	lys	ser	leu	glu	cys	thr	lys
leu	cys	leu	pro	gln	ile	glu	asn						

, or a C- and/or N- terminally shortened sequence thereof;

B) a polypeptide comprising the amino acid sequence:

met leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

C) a polypeptide comprising the amino acid sequence:

met asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn val lys gly thr glu asp
ser gly thr thr

, or a C- and/or N- terminally shortened sequence thereof;

D) a polypeptide comprising the amino acid sequence:

met leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn

asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr

, or a C- and/or N- terminally shortened sequence thereof;

E) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

F) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn

E' cont.

Sub F1 cont

E

asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr

, or a C- and/or N- terminally shortened sequence thereof;

G) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his
leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn

, or a C- and/or N- terminally shortened sequence thereof;

H) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly asp ser val cys pro gln gly lys tyr ile his pro gln
asn asn ser ile cys cys thr lys cys his lys gly thr tyr
leu tyr asn asp cys pro gly pro gly gln asp thr asp cys
arg glu cys glu ser gly ser phe thr ala ser glu asn his

leu arg his cys leu ser cys ser lys cys arg lys glu met
gly gln val glu ile ser ser cys thr val asp arg asp thr
val cys gly cys arg lys asn gln tyr arg his tyr trp ser
glu asn leu phe gln cys phe asn cys ser leu cys leu asn
gly thr val his leu ser cys gln glu lys gln asn thr val
cys thr cys his ala gly phe phe leu arg glu asn glu cys
val ser cys ser asn cys lys lys ser leu glu cys thr lys
leu cys leu pro gln ile glu asn val lys gly thr glu asp
ser gly thr thr

, or a C- and/or N- terminally shortened sequence thereof; and

l) a polypeptide comprising the amino acid sequence:

met gly leu ser thr val pro asp leu leu leu pro leu val
leu leu glu leu leu val gly ile tyr pro ser gly val ile
gly leu val pro his leu gly asp arg glu lys arg asp ser
val cys pro gln gly lys tyr ile his pro gln asn asn ser
ile cys cys thr lys cys his lys gly thr tyr leu tyr asn
asp cys pro gly pro gly gln asp thr asp cys arg glu cys
glu ser gly ser phe thr ala ser glu asn his leu arg his
cys leu ser cys ser lys cys arg lys glu met gly gln val
glu ile ser ser cys thr val asp arg asp thr val cys gly
cys arg lys asn gln tyr arg his tyr trp ser glu asn leu
phe gln cys phe asn cys ser leu cys leu asn gly thr val
his leu ser cys gln glu lys gln asn thr val cys thr cys
his ala gly phe phe leu arg glu asn glu cys val ser cys
ser asn cys lys lys ser leu glu cys thr lys leu cys leu
pro gln ile glu asn val lys gly thr glu asp ser gly thr
thr val leu leu pro leu val ile phe phe gly leu cys leu
leu ser leu leu phe ile gly leu met tyr arg tyr gln arg
trp lys ser lys leu tyr ser ile val cys gly lys ser thr
pro glu lys glu gly glu leu glu gly thr thr thr lys pro
leu ala pro asn pro ser phe ser pro thr pro gly phe thr
pro thr leu gly phe ser pro val pro ser ser thr phe thr
ser ser ser thr tyr thr pro gly asp cys pro asn phe ala
ala pro arg arg glu val ala pro pro tyr gln gly ala asp
pro ile leu ala thr ala leu ala ser asp pro ile pro asn
pro leu gln lys trp glu asp ser ala his lys pro gln ser
leu asp thr asp asp pro ala thr leu tyr ala val val glu
asn val pro pro leu arg trp lys glu phe val arg arg leu

gly	leu	ser	asp	his	glu	ile	asp	arg	leu	glu	leu	gln	asn
gly	arg	cys	leu	arg	glu	ala	gln	tyr	ser	met	leu	ala	thr
trp	arg	arg	arg	thr	pro	arg	arg	glu	ala	thr	leu	glu	leu
leu	gly	arg	val	leu	arg	asp	met	asp	leu	leu	gly	cys	leu
glu	asp	ile	glu	glu	ala	leu	cys	gly	pro	ala	ala	leu	pro
pro	ala	pro	ser	leu	leu	arg							

, or a C- and/or N-terminally shortened sequence thereof.

104. Polypeptide according to claim 103, wherein said polypeptide includes at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and at the carboxyl-terminus.

105. Polypeptide according to claim 104, wherein said polypeptide includes at least one additional amino acid at the carboxyl-terminus.

106. Polypeptide according to claim 103, wherein said polypeptide is not associated with human urinary proteins.--

REMARKS

Claims 40 to 48 and 54 to 66 have been canceled without prejudice or disclaimer. Claims 27, 49, 67, and 68 have been amended to change their dependency. Claims 69 to 106 have been added. Thus, claims 24, 27 to 39, 49 to 53, 67, 68, and 69 to 106 are pending. The amendments and the cancellation of claims have not been made in response to a rejection or in acquiescence to a rejection. The amendments have been made to even more clearly recite the applicants' inventions.

Solely to expedite prosecution, applicants have amended and canceled claims such that the term "variant" is not included in the claims. The terms "variant" (other than "degenerate variants") was not included in the claims as previously examined, and thus, there